SARS-CoV-2 RT-qPCR Detection Kit(SCVPD)
Catalog #RU7038
100 reactions
Product Description
Coronaviruses are a family of large RNA viruses with size ranging from 26 to 32 kb. Theseviruses are zoonotic and in human can cause respiratory infections. As the coronavirus is an
RNA virus it has a relatively high mutation rate resulting in rapid evolution. In December 2019,a new deadly coronavirus known as SARS-CoV-2 (previously known as 2019-nCoV), which hasa high sequence similarity to SARS-CoV, was identified and has caused a pneumonia, known as
Covid-19, outbreak in Wuhan, China and spread globally.
ScienCell's SARS-CoV-2 RT-qPCR Detection Kit (SCVPD) is designed to detect the presenceof SARS-CoV-2 Coronavirus in respiratory specimens and serum samples following CDC
guidelines (see Appendix 1). Please read carefully and follow these guidelines for biosafety
precautions when dealing with possible infectious samples and for obtaining quality data.
Included in the kit are two primer/probe sets (Cat #7038-N1 and 7038-N2) that target
coronavirus SARS-CoV-2 nucleocapsid (N) gene, and the Human RPP30 gene primer/probe set(Cat #7038-RP) that targets exon 1 of human RPP30 gene and serves as a control to assess
specimen quality. In addition, a non-infectious positive control (Cat #7038-Pos) and nucleasefree water are included in the kit. The positive control (Cat #7038-Pos) consists of non-infectious
viral RNA fragments spiked into human small airway epithelial cells and serves to ensure
reagents and instruments are working properly. Please refer to Tables 4 and 5 for resultsinterpretation.
Kit Components
Cat #Component
MB802aOne-Step TaqProbe RT-qPCR master mix, 4x
7038-N1
N gene primer/probe set 1, in solution
7038-N2
N gene primer/probe set 2, in solution
7038-RP
Human RPP30 gene primer/probe set, in solution
7038-H2O Nuclease-free H2O
Positive control (non-infectious;
7038-Pos
RNA: 500 – 1000 copies/μL, cells: 200 – 300 counts/μL)
Additional Materials Required (Materials Not Included in Kit)
Component
Recommended
RNA samples
Customers’ samples
qPCR plate or tube

Quantity
1.5 mL200 μL200 μL200 μL
8 mL

Storage
-20°C
-20°C
-20°C
-20°C
4°C

200 μL-80°C

Quality Control
The primer/probe sets and the positive control are validated by RT-qPCR. The PCR products areanalyzed by gel electrophoresis.
Product Use
For Research Use Only. Not for use in diagnostic procedures.
Shipping and Storage
The product is shipped on dry ice. Upon receipt, store the One-Step TaqProbe RT-qPCR mastermix (Cat #MB802a) and primer/probe sets (Cat #7038-N1, 7038-N2, and 7038-RP) at -20°C in amanual defrost freezer, the positive control (Cat #7038-Pos) at -80°C, and nuclease-free H2O(Cat #7038-H2O) at 4°C.

Procedures
Important: Only use nuclease-free reagents in PCR applications.
1. Prior to use, allow the primer/probe sets (Cat #7038-N1, 7038-N2, and 7038-RP) to thaw
to room temperature in the dark. Shake gently to mix well.
2. Centrifuge the vials at 1,500x g for 1 minute.
3. Aliquot each primer/probe set as needed. Store at -20°C in a manual defrost freezer.
Avoid repeated freeze-and-thaw cycles. Maintain cold and in the dark when thawed.
4. With test samples, two control samples should be run concurrently, the non-infectious
positive control (Cat #7038-Pos), and H2O (Cat #7038-H2O) as the No Template Control(NTC). Prepare three RT-qPCR reactions for each control sample, one with N1primer/probe set, one with N2 primer/probe set, and one with RP primer/probe set.
Prepare 20 µl RT-qPCR reactions for one well as shown in Table 1.
Table 1.
Control sample (Cat #7038-Pos or 7038-H2O)

5 µl

Primer/probe set (N1, N2, or RP)

2 µl

1-step RT-qPCR Master mix, 4x (Cat #MB802a)

5 µl

Nuclease-free H2O (Cat #7038-H2O)

8 µl
Total volume

20 µl

5. For each extracted RNA test sample, prepare three RT-qPCR reactions, one with N1primer/probe set, one with N2 primer/probe set, and one with RP primer/probe set.
Prepare 20 µl RT-qPCR reactions for one well as shown in Table 2.
Table 2.
RNA test sample (concentration varies)

5 µl

Primer/probe set (N1, N2, or RP)

2 µl

1-step RT-qPCR Master mix, 4x (Cat #MB802a)

5 µl

Nuclease-free H2O (Cat #7038-H2O)

8 µl
Total volume

20 µl

6. Seal the RT-qPCR reaction wells. Centrifuge the plates or tubes at 1,500x g for 15
seconds.
7. Setup RT-qPCR reactions as shown in Table 3.
Table 3. Instrument settings for RT-qPCR reactions.

Fluorescence data (FAM) should be collected during the data acquisition step.

Step

Temperature

Time

Number of cycles

UNG incubation

25°C

2 min

1

Reverse transcription

50°C

15 min1

Enzyme activation

95°C

2 min

1

Denaturation

95°C

3 sec

Annealing and extension

55°C

30 secData acquisition

Plate read, detector (FAM)

45

Results Interpretation
Table 4. SCVPD kit control sample test results interpretation.
Sample7038-N1

7038-N27038-RP

Results Interpretation

+

+

+

Expected---

Reverse transcription
and/or PCR failed

-

-

-

Expected

7038-Pos

7038-H2O
If anyone of three targets is positive

Reagent(s) contaminated

Table 5. SCVPD kit target sample test results interpretation when control results are as expected.
7038-N1

7038-N27038-RP

Results Interpretation

+

+

±

SARS-CoV-2 detected±

SARS-CoV-2 detected

If one of two targets is positive--+

SARS-CoV-2 not detected

-

-

-

Invalid result

Appendix 1

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Table of Contents
Introduction .........................................................................................................................................3
Specimens ............................................................................................................................................3
Reagents, Supplies and Equipment Requirements ............................................................................4
Nucleic Acid Extraction ......................................................................................................................5
Quality Control ....................................................................................................................................5
rRT-PCR Assays ..................................................................................................................................6Interpreting Test Results ...................................................................................................................10
Assay Limitations ..............................................................................................................................11
Contact Information .........................................................................................................................12

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Introduction
Purpose: This document describes the use of real-time RT PCR (rT-PCR) assays for the in vitro
qualitative detection of 2019-Novel Coronavirus (2019-nCoV) in respiratory specimens and sera.
The 2019-nCoV primer and probe sets are designed for the universal detection of SARS-like
coronaviruses and for specific detection of 2019-nCoV.
Protocol Use Limitations: The rRT-PCR assays described here have not been validated for platforms
or chemistries other than those described in this document.
Specimens
Biosafety Precautions
Wear appropriate personal protective equipment (e.g. gowns, gloves, eye protection) when working
with clinical specimens. Specimen processing should be performed in a certified class II biologicalsafety cabinet following biosafety level 2 or higher guidelines. For more information, refer to:Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients
Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV)
https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html
Biosafety in Microbiological and Biomedical Laboratories 5th edition available at
http://www.cdc.gov/biosafety/publications/.
Acceptable Specimens
Respiratory specimens including: nasopharyngeal or oropharyngeal aspirates or washes,
nasopharyngeal or oropharyngeal swabs, broncheoalveolar lavage, tracheal aspirates, andsputum.
o Swab specimens should be collected only on swabs with a synthetic tip (such aspolyester or Dacron®) with aluminum or plastic shafts. Swabs with calcium alginate
or cotton tips with wooden shafts are not acceptable.
Serum
Specimen Handling and Storage
Specimens can be stored at 4oC for up to 72 hours after collection.
If a delay in extraction is expected, store specimens at -70oC or lower.
Extracted nucleic acids should be stored at -70oC or lower.
Specimen Rejection criteria:
Specimens not kept at 2Incomplete specimen labeling or documentation.
Inappropriate specimen type.
Insufficient specimen volume.

-70°C or below.

Reagents, Supplies and Equipment Requirements
2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Disclaimer: Names of vendors or manufacturers are provided as examples of suitable productsources. Inclusion does not imply endorsement by the Centers for Disease Control and Prevention.
Reagents and Supplies
rRT-PCR primer/probe sets
Positive template control
TaqPath™ 1-Step RT-qPCR Master Mix, CG (ThermoFisher; cat # A15299)
Molecular grade water, nuclease-free
Disposable powder-free gloves
P2/P10, P200, and P1000 aerosol barrier tips
Sterile, nuclease-free 1.5 mL microcentrifuge tubes
0.2 mL PCR reaction tube strips or 96-well real-time PCR reaction plates and optical 8-cap
stripsLaboratory marking pen
Cooler racks for 1.5 microcentrifuge tubes and 96-well 0.2 mL PCR reaction tubes
Racks for 1.5 ml microcentrifuge tubes
Acceptable surface decontaminantso DNAZapTM (Life Technologies, cat. #AM9890)
o DNA AwayTM (Fisher Scientific; cat. #21-236-28)
o RNAse AwayTM (Fisher Scientific; cat. #21-236-21
o 10% bleach (1:10 dilution of commercial 5.25-6.0% sodium hypochlorite)
Equipment
PCR Work Station [UV lamp; Laminar flow (Class 100 HEPA filtered)]
Vortex mixer
Microcentrifuge
Micropipettes (2 or 10 µl, 200 µl and 1000 µl)
Multichannel micropipettes (5-50 µl)
2 x 96-well cold blocks-20oC (nonfrost-free) and -70oC freezers; 4oC refrigerator
Real-time PCR detection system
Nucleic acid extraction system

Nucleic Acid Extraction
Performance of rRT-PCR amplification based assays depends on the amount and quality ofsample template RNA. RNA extraction procedures should be qualified and validated forrecovery and purity before testing specimens.
Commercially available extraction procdures that have been shown to generate highly purified
RNA when following manufacturer’s recommended procedures for sample extraction include:
bioMérieux NucliSens® systems, QIAamp® Viral RNA Mini Kit, QIAamp® MinElute Virus
Spin Kit or RNeasy® Mini Kit (QIAGEN), EZ1 DSP Virus Kit (QIAGEN), Roche MagNA Pure2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Compact RNA Isolation Kit, Roche MagNA Pure Compact Nucleic Acid Isolation Kit, andRoche MagNA Pure 96 DNA and Viral NA Small Volume Kit, and Invitrogen ChargeSwitch®
Total RNA Cell Kit.
Retain residual specimen and nucleic extract and store immediately at -70oC.
Only thaw the number of specimen extracts that will be tested in a single day. Do notfreeze/thaw extracts more than once before testing.

Quality Control
Due to the sensitivity of rRT-PCR, these assays should be conducted using strict quality control andquality assurance procedures. Following these guidelines will help minimize chance of falsepositive amplification.
General Considerations
Personnel must be familiar with the protocol and instruments used.
Maintain separate areas and dedicated equipment (e.g., pipettes, microcentrifuges) andsupplies (e.g., microcentrifuge tubes, pipette tips, gowns and gloves) for assay reagent setup
and handling of extracted nucleic acids.
Work flow must always be from the clean area to the dirty area.
Wear clean disposable gowns and new, previously unworn, powder-free gloves during assay
reagent setup and handling of extracted nucleic acids. Change gloves whenevercontamination is suspected.
Store primer/probes and enzyme master mix at appropriate temperatures (see package
inserts). Do not use reagents beyond their expiry dates.
Keep reagent tubes and reactions capped as much as possible.
Clean and decontaminate surfaces.
Do not bring extracted nucleic acid or PCR products into the assay setup area.
Use aerosol barrier (filter) pipette tips only.
Use PCR plate strip caps only. Do not use PCR plate sealing film.
Assay Controls
Assay controls should be run concurrently with all test samples.
PTC - positive template control with an expected Ct value range
NTC - negative template control added during rRT-PCR reaction set-up
HSC – human specimen extraction control extracted concurrently with the test samples;
provides a nucleic acid extraction procedural control and a secondary negative control thatvalidates the nucleic extraction procedure and reagent integrity
RP - all clinical samples should be tested for human RNAse P (RNP) gene to assess
specimen quality
Note: Keep running logs of PTC performance. After each rRT-PCR run of clinical samples,the control Ct values should be recorded.

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

rRT-PCR Assays
Stock Reagent PreparationrT-PCR Primers/Probe Sets (see package insert if provided by CDC)
Precautions: These reagents should only be handled in a clean area and stored at appropriate
temperatures (see below) in the dark. Freeze-thaw cycles should be avoided. Maintain cold
when thawed.
-free water (50X
working concentration) and allow to rehydrate for 15 min at room temperature in the dark.
volumes into 5 pre-labeled tubes. Store asingle aliquot of primers/probe at 2-8oC in the dark. Do not refreeze (stable for up to 4
-20oC in a non-frost-free freezer.
Positive Template Control (PTC) (if using CDC positive control, nCoVPC, see package insert
provided by CDC)
Precautions: This reagent should be handled with caution in a dedicated nucleic
acid handling area to prevent possible contamination. Freeze-thaw cycles should
be avoided. Maintain on ice when thawed.
Used to assess performance of rRT-PCR assays. Unless already hydrated,suspend dried reagent in each tube in 1 mL of nuclease-free water to achieve the-70°C.
To make working dilutions of nCo
nCoVPC from above and dilute 1:10 (final volume 1.0 mL). Dispense diluted
nCoVPC into single use aliquots suitable for your testing needs. Store unused-70°C.
Thaw a single aliquot of diluted positive control for each experiment and holdon ice until adding to plate. Discard any unused portion of the aliquot.
The nCoVPC also contains human DNA that serves as the positive control for
the RP assay.

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Equipment preparation
1) Clean and decontaminate all work surfaces, pipets, centrifuges and other equipment prior touse using RNase Away® or 10% freshly prepared bleach.
2) Turn on AB 7500 Fast DX and allow block to reach optimal temperature.
3) Perform plate set up and select cycling protocol on the instrument.
4) Instrument Settings: Detector (FAM); Quencher (None); Passive Reference: (None); Run
Mode: (Standard); Sample Volume (25 µL)
Step
UNG Incubation
RT incubation
Enzyme activation

Cycles1
1
1

Amplification

45

Temp
25oC
50oC
95oC
95oC
55oC

Time
2 min
15 min2 min
3 sec
30 sec* Fluorescence data (FAM) should be collected during the 55°C incubation step.
Reaction Master Mix and Plate Set-Up
Note: Plate set-up configuration can vary with the number of specimens and work day
organization. NTCs and nCoVPCs must be included in each run.
1) In the reagent set-up room clean hood, place rRT-PCR buffer, enzyme, and primer/probes
on ice or cold-block. Keep cold during preparation and use.
2) Thaw 2X Reaction Mix prior to use.
3) Mix buffer, enzyme, and primer/probes by inversion 5 times.
4) Briefly centrifuge buffer and primers/probes and return to ice.
5) Label one 1.5 mL microcentrifuge tube for each primer/probe set.
6) Determine the number of reactions (N) to set up per assay. It is necessary to make excess
reaction mix for the NTC, nCoVPC, and RP reactions and for pipetting error. Use thefollowing guide to determine N:
If number of samples (n) including controls equals 1 through 14, then N = n + 1
If number of samples (n) including controls is 15 or greater, then N = n + 2
For each primer/probe set, calculate the amount of each reagent to be added for eachreaction mixture (N = # of reactions).
TaqPath™ 1-Step RT-qPCR Master Mix
Step #

Reagent

Vol. of Reagent Added
per Reaction

1

Nuclease-free Water

N x 13.5 µL

2Combined Primer/Probe Mix

N x 1.5 µL

3TaqPathTM 1-Step RT-qPCR Master Mix (4x)N x 5.0 µL

Total Volume

N x 20.0 µL

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

8) Dispense reagents into each respective labeled 1.5 mL microcentrifuge tube. After additionof the reagents, mix reaction mixtures by pipetting up and down. Do not vortex.
9) Centrifuge for 5 seconds to collect contents at the bottom of the tube, and then place the tube
in a cold rack.
10) Set up reaction strip tubes or plates in a 96-well cooler rack.
11) Dispense 20 µL of each master mix into the appropriate wells going across the row as shown
below (Figure 1):
Figure 1: Example of Reaction Master Mix Plate Set-Up
1

2

3

4

5

6

7

8

9

10

11

12

A

N1

N1

N1

N1

N1

N1

N1

N1

N1

N1

N1

N1

B

N2

N2

N2

N2

N2

N2

N2

N2

N2

N2

N2

N2

C

N3

N3

N3

N3

N3

N3

N3

N3

N3

N3

N3

N3

D

RP

RP

RP

RP

RP

RP

RP

RP

RP

RP

RP

RP

E
F
G
H

12) Prior to moving to the nucleic acid handling area, prepare the No Template Control (NTC)

reactions for column #1 in the assay preparation area.
13) Pipette 5 µL of nuclease-free water into the NTC sample wells. Securely cap NTC wells
before proceeding.
14) Cover the entire reaction plate and move the reaction plate to the specimen nucleic acidhandling area.
Template Addition
1) Gently vortex nucleic acid sample tubes for approximately 5 seconds.
2) After centrifugation, place extracted nucleic acid sample tubes in the cold rack.
3) Samples should be added to column 2-11 (column 1 and 12 are for controls) to the specificassay that is being tested as illustrated in Figure 2. Carefully pipette 5.0 µL of the firstsample into all the wells labeled for that sample (i.e. Sample “S1” down column #2). Keepother sample wells covered during addition. Change tips after each addition.
4) Securely cap the column to which the sample has been added to prevent cross contaminationand to ensure sample tracking.
5) Change gloves often and when necessary to avoid contamination.
2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

6) Repeat steps #3 and #4 for the remaining samples.
7) If necessary, add 5 µL of Human Specimen Control (HSC) extracted sample to the HSC

wells (Figure 2, column 11). Securely cap wells after addition
8) Cover the entire reaction plate and move the reaction plate to the positive template control
handling area.
Assay Control Addition
1) Pipette 5 µL of nCoVPC RNA to the sample wells of column 12 (Figure 2). Securely cap
wells after addition of the control RNA.
NOTE: If using 8-tube strips, label the TAB of each strip to indicate sample position. DO NOTLABEL THE TOPS OF THE REACTION TUBES!
2) Briefly centrifuge reaction tube strips for 10-15 seconds. After centrifugation return to coldrack.
NOTE: If using 96-well plates, centrifuge plates for 30 seconds at 500 x g, 4°C.
Figure 2. 2019-nCoV rRT-PCR Diagnotic Panel: Example of Sample and Control Set-up
1

2

3

4

5

6

7

8

9

10

11a

A

NTC

S1

S2

S3

S4

S5

S6

S7

S8

S9

S10

B

NTC

S1

S2

S3

S4

S5

S6

S7

S8

S9

S10

C

NTC

S1

S2

S3

S4

S5

S6

S7

S8

S9

S10

D

NTC

S1

S2

S3

S4

S5

S6

S7

S8

S9

S10

12
nCoV
PC
nCoV
PC
nCoV
PC
nCoV
PC

E
F
G
H
a

Replace the sample in this column with extracted HSC if necessary

Data Analysis
1) After completion of the run, save and analyze the data following the instrument
manufacturer’s instructions. Analyses should be performed separately for each target using
a manual threshold setting. Thresholds should be adjusted to fall within exponential phaseof the fluorescence curves and above any background signal (refer to Figure 3). The
procedure chosen for setting the threshold should be used consistently.

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

Figure 3. Amplification Plot Window

Interpreting Test Results
NTCs should be negative and not exhibit fluorescence growth curves that cross the thresholdline.
o If a false positive occurs with one or more of the primer and probe NTC reactions, sample
contamination may have occurred.
Invalidate the run and repeat the assay with stricter adherence to the procedure
guidelines.
PTC reaction should produce a positive result with an expected Ct value for each target
included in the test.
o If expected positive reactivity is not achieved, invalidate the run and repeat the assay withstricter adherence to procedure guidelines.
o Determine the cause of failed PTC reactivity, implement corrective actions, anddocument results of the investigation and corrective actions.
o Do not use PTC reagents that do not generate expected result.
RP should be positive at or before 35 cycles for all clinical samples and HSC, thus indicating
the presence of sufficient nucleic acid from human RNase P gene and that the specimen is ofacceptable quality.
2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

o Failure to detect RNase P in HSC may indicate:
Improper assay set up and execution
Reagent or equipment malfunctiono Detection of RNase P in HSC but failure to detect RNase P in any of the clinicalsamples may indicate:
Improper extraction of nucleic acid from clinical materials
resulting in loss of nucleic acid or carry-over of PCR inhibitorsfrom clinical specimens
Absence of sufficient human cellular material in sample toenable detection
HSC should be negative for 2019-nCoV specific primer/probe sets.
o If any 2019-nCoV specific primer/probes exhibit a growth curve thatcrosses the threshold line, interpret as follows:
Contamination of nucleic acid extraction reagents may have occurred.
Invalidate the run and confirm reagent integrity of nucleic acid extraction
reagents prior to further testing.
Cross contamination of samples occurred during nucleic acid extraction
procedures or assay setup. Invalidate the run and repeat the assay with stricter
adherence to procedure guidelines.
When all controls exhibit the expected performance, a specimen is considered negative if all
2019-nCoV markers (N1, N2, N3) cycle threshold growth curves DO NOT cross the threshold
AND the RNase P growth curve DOES cross the threshold line.
When all controls exhibit the expected performance, a specimen is considered positive for
2019-nCoV if all markers (N1, N2, N3) cycle threshold growth curve crosses the thresholdline. The RNase P may or may not be positive as described above, but the 2019-nCoV result
is still valid.
When all controls exhibit the expected performance and the growth curves for the 2019-nCoV
markers (N1, N2, N3) AND the RNase P marker DO NOT cross the cycle threshold growth
curve, the result is invalid. The extracted RNA from the specimen should be re-tested. If
residual RNA is not available, re-extract RNA from residual specimen and re-test. If the retested sample is negative for all markers and all controls exhibit the expected performance,
the result is “Invalid.”
When all controls exhibit the expected performance and the cycle threshold growth curve forany one or two markers, (N1, N2, N3) but not all three crosses the threshold line the result ininconclusive for 2019-nCoV. Re-extract RNA from residual specimen and re-test.

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020

2019-nCoV rRT-PCR Diagnostic Panel Results Interpretation
2019
nCoV_N1

2019
nCoV_N2

2019
nCoV_N3

RP

ResultInterpretationa

+

+

+

±

2019-nCoV detected±

Inconclusive Result

If only one, or two, of three targets is positive
-

-

-

+

2019-nCoV notdetected

-

-

-

-

Invalid Result

Assay Limitations
Analysts should be trained and familiar with testing procedures andinterpretation of results prior to performing the assay.
A false negative result may occur if inadequate numbers of organisms arepresent in the specimen due to improper collection, transport or handling.
RNA viruses in particular show substantial genetic variability. Although efforts were madeto design rRT-PCR assays to conserved regions of the viral genomes, variability resulting in
mis-matches between the primers and probes and the target sequences can result in
diminished assay performance and possible false negative results.

Contact Information
Suggestions and questions concerning this procedure may be sent to:
respvirus@cdc.gov.

2019-nCoV rRT-PCR Panel
Instructions for Use

CDC/NCIRD/DVD

Effective: 24 Jan 2020